Enovis (ENOV) Projected to Post Earnings on Thursday

Enovis (NYSE:ENOV) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Enovis to post earnings of $0.74 per share and revenue of $555.80 million for the quarter. Enovis has set its FY 2025 guidance at 2.950-3.100 EPS.

Enovis (NYSE:ENOV) last released its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. Enovis had a positive return on equity of 5.99% and a negative net margin of 37.65%. The business had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same quarter last year, the business posted $0.50 earnings per share. The business’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, analysts expect Enovis to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Enovis Trading Down 1.0%

Shares of ENOV opened at $27.05 on Thursday. The firm’s fifty day moving average is $31.27 and its two-hundred day moving average is $36.24. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52. The stock has a market cap of $1.55 billion, a PE ratio of -1.94 and a beta of 1.70. Enovis has a 52-week low of $25.93 and a 52-week high of $49.83.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC boosted its stake in Enovis by 13.0% in the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock valued at $249,000 after acquiring an additional 749 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,072 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after purchasing an additional 73,116 shares during the period. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on ENOV shares. Canaccord Genuity Group decreased their target price on shares of Enovis from $75.00 to $70.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Evercore ISI decreased their target price on shares of Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. JMP Securities decreased their price target on Enovis from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research note on Friday, May 9th. Finally, Needham & Company LLC lowered their price objective on shares of Enovis from $64.00 to $57.00 and set a “buy” rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.60.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.